维生素E有什么希望？
Is There Any Hope for Vitamin E？
摘要
过去15年来，有关动脉粥样硬化的流行病学、基础生物学和实验研究均支持下述假设：抗氧化剂可通过抑制动脉壁低密度脂蛋白的氧化而抑制动脉粥样硬化的发生。这种作用机制可抑制胆固醇酯通过巨噬细胞清除受体在动脉斑块内发生病理性沉积。胆固醇酯病理沉积是一种可引起斑块破裂及心血管事件的过程。同样，生物机制亦已确定，癌基因可被抗氧化剂阻断。
出处
《美国医学会杂志（中文版）》
2006年第2期124-126,共3页
The Journal of the American Medical Association(Chinese Edition)
参考文献38
-
1Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC.Vitamin E consumption and the risk of coronary disease in women, N Engl J Med.1993 ;328:1444-1449
-
2Rimm EB, Stampfer M J, Ascherio A, Giovannucci E, Colditz GA, Willett WC.Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
-
3Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis.J Clin Invest, 1991;88:1785-1792.
-
4Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radio Res Commun. 1989;6:67-75.
-
5Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986;77:641-644.
-
6Sparrow CP, Doebber TW, Olszewski J, et al. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterolfed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine. J Clin Invest. 1992;89:1885-1891.
-
7Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987;84:7725-7729.
-
8Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemiainduced atherosclerosis in the nonhuman primate by probucol I: is the extent of atherosclerosls related to resistance of LDL to oxidation? J Clin Invest. 1994 94:155-164.
-
9Brown BG, Zhao XQ, Sacco DE, Albers J J, Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
-
10Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
-
1谢海波.可否减掉重复的调脂药[J].家庭医药（就医选药）,2015,0(5):58-58.
-
2贺晓楠,陈宇,张桂华.转换酶抑制剂和长效钙拮抗剂对动脉硬化相关因子NO、ET影响的对比研究[J].吉林医学,2003,24(6):503-504.
-
3诸葛欣,张蕴,曹肇慧.血栓素受体在动脉粥样硬化中的作用[J].国外医学（老年医学分册）,2008,29(1):9-12. 被引量：2
-
4张志来,陈建华.定向进化技术在蛋白质开发中的应用进展[J].中国医药生物技术,2014,9(6):464-466.
-
5吴茂礼,李建军,杨士芝,魏淑红.普伐他汀消退老年人动脉粥样斑块的疗效观察[J].中国老年保健医学,2008,6(6):28-29.
-
6黄振华.脉血康胶囊联合阿托伐汀治疗颈动脉粥样硬化患者动脉斑块的疗效[J].海峡药学,2015,27(2):109-110. 被引量：7
-
7苏德国,孔繁呈,鲍利改.急性脑梗死患者血浆LIGHT的变化及其临床意义[J].解放军药学学报,2015,31(2):145-147.
-
8肖敏,徐洪来.凝集素生物机制的研究进展[J].华夏医学,2013,26(1):189-193. 被引量：1
-
9柯昭民,张文荣.探讨他汀类药物在预防脑梗死中的应用[J].当代医学,2012,18(3):132-133. 被引量：6
-
10唐启卫.缬沙坦对颈动脉不稳定斑块稳定性的影响[J].中国药师,2007,10(12):1195-1197.
